A meta-analysis of 40 studies found aggressive-variant prostate cancer was linked to shorter progression-free and overall survival. Platinum-based chemotherapy showed higher response rates than non-platinum regimens.
The FDA has approved a monthly subcutaneous dosing schedule for Johnson & Johnson's Rybrevant Faspro for EGFR-mutated NSCLC, based on PALOMA-2 trial data showing 82-87% response rates. The approval follows the drug's initial biweekly dosing approval in December 2025 and offers reduced administration time and reactions compared to intravenous delivery.
Trastuzumab deruxtecan is moving into earlier treatment lines for HER2-positive metastatic breast cancer, demonstrating superior efficacy over standard regimens and prompting reconsideration of long-standing treatment sequences.
A randomized trial of 210 advanced lung cancer patients found that administering checkpoint inhibitor immunotherapy in the morning nearly doubled progression-free survival and extended overall survival by nearly a year compared to later-day dosing.
